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Abstract
Background: CELF/Bruno-like proteins play multiple roles, including the regulation of alternative splicing and
translation. These RNA-binding proteins contain two RNA recognition motif (RRM) domains at the N-terminus and
another RRM at the C-terminus. CUGBP2 is a member of this family of proteins that possesses several alternatively
spliced exons.
Results: The present study investigated the expression of exon 14, which is an alternatively spliced exon and
encodes the first half of the third RRM of CUGBP2. The ratio of exon 14 skipping product (R3δ) to its inclusion was
reduced in neuronal cells induced from P19 cells and in the brain. Although full length CUGBP2 and the CUGBP2
R3δ isoforms showed a similar effect on the inclusion of the smooth muscle (SM) exon of the ACTN1 gene, these
isoforms showed an opposite effect on the skipping of exon 11 in the insulin receptor gene. In addition,
examination of structural changes in these isoforms by molecular dynamics simulation and NMR spectrometry
suggested that the third RRM of R3δ isoform was flexible and did not form an RRM structure.
Conclusion: Our results suggest that CUGBP2 regulates the splicing of ACTN1 and insulin receptor by different
mechanisms. Alternative splicing of CUGBP2 exon 14 contributes to the regulation of the splicing of the insulin
receptor. The present findings specifically show how alternative splicing events that result in three-dimensional
structural changes in CUGBP2 can lead to changes in its biological activity.
Background
The CELF (CUGBP and ETR-3 Like Factor)/Bruno-like
protein family plays important roles in the regulation of
alternative splicing and translation [1-5]. In mammals, the
CELF/Bruno-like family includes six members and is clas-
sified into two subgroups based on overall sequence simi-
larity. One group is composed of CUGBP1 and CUGBP2,
which share 76% amino acid sequence identity [6]. The
other group contains BRUNOL1 (CELF3), BRUNOL5
(CELF5), BRUNOL6 (CELF6), and CELF4, which share
62-66% a.a. sequence identity with each other and 44%
sequence identity with CUGBP1 [6]. CELF proteins have
two consecutive RNA recognition motifs (RRMs) (RRM1-
2) in the N-terminal region and another RRM (RRM3) in
the C-terminal region. RRM2 and RRM3 are separated by
a linker region that consists of 160-230 amino acids. CELF
family members are expressed in multiple tissues with a
distinct tissue distribution pattern. CUGBP1 is expressed
in almost all tissues, BRUNOL1 and BRUNOL5 are
restricted to the brain, and CUGBP2 is abundant in the
heart, skeletal muscle, and brain [5,6].
The CELF family protein CUGBP1 was originally identi-
fied as an RNA-binding protein for CUG triplet repeats
observed in the 3’ UTR of the dystrophy myotonica
protein kinase (DMPK) mRNA [7]. Increased copies of
CUG triplet repeats from 5-37 to 50-5,000 cause myotonic
dystrophy type I. CUGBP1 regulates the alternative spli-
cing of exon 5 of cardiac Troponin T (cTNT) via the CUG
repeats of muscle-specific enhancer elements (MSE) in its
pre-mRNAs [1]. CUGBP1 is presumably involved in the
incidence of DM because the splicing of cTNT was dis-
rupted in DM striated muscle. In addition to its role in the
regulation of cTNT exon 5 splicing, CUGBP1 is thought
to be involved in controlling the alternative splicing of
amyloid precursor protein (APP) [8], muscle-specific
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chloride channel [9,10], a-actinin (ACTN1) [11,12], and
the insulin receptor (IR) [13,14]. CUGBP2 (also known as
ETR-3, Napor, and Brunol3), a paralogous protein of
CUGBP1, is also known as an alternative splicing regula-
tor. Similar to CUGBP1, CUGBP2 activates the inclusion
of exon 5 in human cTNT mRNA via binding to MSE
[3,15]. CUGBP2 induces smooth muscle-specific exon
inclusion via binding to uridine purine repeat elements
(URE) in ACTN1 [11,12]. Although CUGBP2 is known as
a splicing activator for the N-methyl-D-aspartate receptor
1 (NMDA R1) exon 21, CUGBP2 represses NMDA R1
exon 5 inclusion [16]. In addition, CUGBP2 was reported
to repress the inclusion of the IR exon 11 [17]. These stu-
dies showed that CUGBP2 has positive and negative regu-
latory roles in alternative splicing.
Bruno, another member of this protein family, is a trans-
lational repressor involved in germ cell formation in
Drosophila [2]. The Bruno protein binds to the BRE
(Bruno-responsive element) of the 3’ UTR of oskar mRNA
and represses its translation in the oocyte. The oskar pro-
tein is responsible for germ cell formation in the cyto-
plasm of the posterior pole of the oocyte. In vertebrates,
EDEN-BP (embryo deadenylation element-binding pro-
tein), an orthologous protein of CUGBP1 in Xenopus, has
been reported to control the translational regulation activ-
ity of specific maternal mRNAs via the EDEN sequence
[18]. In addition, not only Bruno-like mRNA but also its
protein, which is an orthologous protein of CUGBP1 in
zebrafish, localized to the germplasm at the end of the
cleavage furrow [11,19,20]. These results suggest that
CUGBP1 is involved in translational control and germ cell
formation.
The binding sequences of CUGBP2 and CUGBP1 can
be classified into two groups. One group is represented
by CUG triplet repeats of cTNT, Mt-PK, DMPK and C/
EBPb [1,7,21], where the binding sequence essentially
contains CUG repeats. Another group is represented by
the BRE of oskar, EDEN of Eg5 and URE of ACTN1
[2,11,18], and the binding sequence essentially contains
uridine and guanine (UG)-repeats. Although there are
three RRMs responsible for RNA-binding in CUGBPs,
previous studies concluded that the RRM3 of CUGBPs
binds to the UG-repeat in a sequence-specific manner
[22]. Contradictory results showed that consecutive
RRM1-2s bind to RNA in a sequence-specific manner. In
addition to RRMs, the amino acids surrounding the
RRMs were reported to affect RNA-binding and splicing
activities. Indeed, RRM1-2 plus 70 residues of the adja-
cent downstream linker and RRM3 plus the last 119
amino acids of the adjacent upstream linker activated the
MSE-dependent exon inclusion of cTNT [15,17].
Most of the mammalian genes, including CUGBP2, are
transcribed as alternatively spliced variants. Among the
alternative exons of CUGBP2, the present study focused
on the skipping of exon 14, which encodes the first half
of RRM3. Generally, an RRM is composed of two
a-helixes and four b-sheets (b1-a1-b2-b3-a2-b4) formed
by almost 80 a.a. [23]. The well-conserved RNP-1 and
RNP-2 correspond to the third b-sheet (b3) and first b-
sheet (b1), respectively. RNP-1 is important for the inter-
calation of target RNA in a sequence-specific manner
[24]. Because exon 14 of the CUGBP2 gene encodes the
first half of RRM3, a skipping transcript produces
CUGBP2 truncated in parts of RRM3 (CUGBP2 R3δ).
Similar to CUGBP2 R3δ, there are many proteins that
encode unusual or partially truncated RRM domains in
the database (Table 1). U2AF35 has an unusual RRM
called the U2 homology motif (UHM) and its interaction
with U2AF65 strengthens RNA binding [25,26]. More-
over, many proteins that contain partially deleted RRMs
appear to be generated by alternative splicing. However,
it is unclear how these proteins with partially truncated
RRMs caused by alternative splicing function in biologi-
cal processes.
The present study examined the expression patterns of
CUGBP2 mRNA and its isoform, R3δ, in P19 cells during
neural differentiation and in different tissues. CUGBP2
was highly expressed in neural cells and in the adult brain
compared with R3δ, which was the major product in the
kidneys, liver and undifferentiated P19 cells. Transient
transfection experiments showed similar activities of
CUGBP2 and R3δ, and both proteins promoted the use of
the SM (smooth muscle) exon instead of the NM (non-
muscle) exon of the ACTN1 minigene. On the other hand,
CUGBP2 and R3δ had opposite effects on alternative spli-
cing of exon 11 of IR; CUGBP2 repressed IR exon 11
inclusion, whereas R3δ did not and even slightly increased
inclusion. This result suggests that the alternatively spliced
isoform, R3δ, has a different function from that of
CUGBP2. In addition, the results of molecular dynamics
(MD) and NMR showed that the structure of the RRM
domain differs significantly from that in the R3δ isoform,
resulting in the disruption of its binding activity.
Results and discussion
Alternative splicing of CUGBP2
A search of the UCSC genome browser, BLAT, suggested
that the R3δ isoform is the product of skipping of exon
14 in 25% of CUGBP2 transcripts. Exon14 is 144 nt and
the skipping transcript does not generate a new prema-
ture termination codon. To assess in which organ alter-
native splicing of RRM3 in CUGBP2 takes place, RT-PCR
was performed in adult mouse tissues. The products of
exon 14 inclusion (CUGBP2) and exon 14 skipping (R3δ),
which encode a complete and partial RRM3, respectively,
were detected (Figure 1A &1B). CUGBP2 mRNA was
highly expressed in the brain, where the main product
was the exon 14 inclusion transcript encoding a complete
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RRM3 (Figure 1C, R3δ percentage of CUGBP2 and R3δ
in the brain: 8.1%). The total amount of CUGBP2 tran-
scripts in the kidney or liver was low compared to that in
brain, but the percentage of the R3δ isoform was rela-
tively high (Figure 1C, R3δ percentage of CUGBP2 and
R3δ in the kidney: 22.1%; in the liver, 19.5%). These
results suggest that the R3δ isoform is one of major pro-
ducts when their gene expression of CUGBP2 is low, and
the CUGBP2 isoform, but not R3δ, is expressed as the
major product when their gene expression is high. To
further investigate the alternative splicing pattern of
CUGBP2, RT-PCR was performed in P19 cells during
neural differentiation. Increased levels of the exon
14 inclusion product were detected during neural differ-
entiation even though the exon 14 skipping product was
not essentially changed (Figure 1D). The R3δ percentage
on day 7 (neural cell stage) was 18.9%, which was the
lowest during P19 neural differentiation (R3δ was 29.3%
in undifferentiated P19 cells). The relatively low expres-
sion of R3δ with respect to alternative splicing patterns
was also found in tissues of the adult mouse. Western
blot analysis of CUGBP2 proteins showed that the full
length isoform was the main protein in P19 cells and that
its level increased at the neural stage. By contrast, the
level of R3δ decreased at the neural stage, although it was
observed in undifferentiated P19 cells (Figure 1E).
Expression analysis of CUGBP2 target genes, ACTN1 and
insulin receptor
CUGBP2 is a regulator of the alternative splicing of several
transcripts, including ACTN1 [11] and IR [17]. The alter-
native splicing of ACTN1 and IR was therefore analyzed in
adult mouse tissues and P19 cells. The ACTN1 gene has
mutually exclusive exons, namely the smooth muscle (SM)
exon and non-muscle (NM) exon (Figure 2A). The SM
exon., as a percentage of NM and SM exons, was higher in
neural differentiated P19 cells (28.6%) than in undifferen-
tiated P19 cells (6.7%, Figure 2B). In the brain, 83.7% of
ACTN1 transcripts contained the SM exon, while the NM
exon was predominant in the kidney (SM exon: 26.6%)
Table 1 List of partial RRMs from the BLAST search
Gene Isoforms Total RRMs Short RRM Lacking Tandem Alternative
CELF4 4 3 3rd N-ter RRM1-2 Isoform 1/2/3
CPEB1 3 2 2nd C-ter RRM1-2 -
EIF3B 1 1 1st N-ter - -
EIF4B 1 1 1st C-ter - -
HNRPAB 2 2 2nd C-ter RRM1-2 -
HNRPLL 2 3 1st C-ter RRM1-2 -
HTATSF1 1 2 2nd N- & C-ter - -
LEMD3 2 1 1st N-ter - -
LOC100132919 1 1 1st C-ter - -
NONO 2 2 1st N-ter RRM1-2 Isoform 1
RBM10 2 2 1st N-ter - Isoform 1
RBM24 2 1 1st N-ter - Isoform 1/3
RBM28 2 3 (4) 1st (2nd) C-ter - Isoform 1
RBM34 2 1 (2) 1st C-ter RRM1-2 Isoform 1
RBMS1 2 2 1st C-ter RRM1-2 -
RBMS2 1 2 1st C-ter RRM1-2 -
RBMS3 1 2 1st C-ter RRM1-2 -
RDM1 8 1 1st N-ter - Isoform1/2/3/4
ROD1 3 4 1st C-ter - -
RRP7A 1 1 1st C-ter - -
SRSF1 2 2 1st C-ter - -
SSB 1 2 1st C-ter - -
SYNCRIP 6 3 2nd C-ter RRM1-3 Isoform1/2/5/6
TARDBP 1 2 2nd C-ter RRM1-2 -
U2AF1 3 1 1st N-ter - -
U2AF2 2 3 3rd N-ter RRM1-2 -
UHMK1 3 1 1st N-ter - Isoform 3
The list shows human proteins possessing an RRM with a deleted part selected from human RefSeq proteins. In 53 human Among 457 human RRM-type
proteins, 53 human RefSeq proteins (27 human genes) showed a severely disrupted RRM domain. When two RRM domains have a short linker region (less than
50 a.a), these RRMs were considered as tandem RRMs. When an alternatively spliced isoform restored the complete RRM, the name of the isoform was listed. The
parentheses show RRMs that were removed form the alternatively spliced isoforms.
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and liver (Figure 2C, SM exon: 7.6%). CUGBP2 has been
suggested to promote the inclusion of the SM exon in
prior work [11,12], suggesting that the elevated expression
of CUGBP2 and inclusion of the ACTN1 SM exon may
occur in the same cells and tissues.
On the other hand, the IR gene consists of 22 exons
and generates 2 isoforms, IR-A and IR-B, which are char-
acterized by the skipping and inclusion of exon 11,
respectively (Figure 2A) [28]. RT-PCR analysis of the
alternative splicing of the IR gene in tissues and P19 cells
identified the two isoforms, IR-A and IR-B, in P19 cells
during neural differentiation (Figure 2B). Although the
expression of the IR gene increased during the glial cell
stage, the IRA/IR-B ratio did not change significantly
during cell differentiation (the IR-A form, as percentage
of IR-A and IR-B, was 86.4% in undifferentiated P19 cells
and 80.7% in neural differentiated P19 cells). While the
exon 11 skipping variant IR-A was expressed in the brain
(IR-A: 87.6%), the exon 11 inclusion form IR-B was
mainly expressed in the kidney (IR-A: 4.3%) and liver
(IR-A: 5.0%). Because CUGBP2 is known to repress the
inclusion of IR exon 11 [17], elevated expression of
CUGBP2 and the IR-A variant may occur in the same tis-
sues, but is not observed in P19 cells. In addition to the
expression of CUGBP2, the ratio of R3δ to CUGBP2 was
lower in the brain than in the kidney and liver. The func-
tion of the R3δ isoform was therefore examined in detail
as described in the next section.
CUGBP2 R3δ induces smooth muscle type splicing of
ACTN1
As described previously, CUGBP2 promotes the inclusion
of the mutually exclusive SM exon instead of the NM
exon in ACTN1 [11,12]. The specific function of the
CUGBP2 isoform R3δ was examined by transient trans-
fection using the mouse ACTN1 minigene (Figure 3A).
Transfection of COS7 cells with the ACTN1 minigene
alone resulted in the detection of a transcript including
the NM exon as a major product and another transcript
with the SM exon as a minor product (Figure 3B). Con-
trol COS7 cells lacking the minigene did not show these
transcripts, confirming that the two transcripts contain-
ing the NM or SM exon were products of the transfected
minigene. Co-transfection with a myc-tagged CUGBP2
Figure 1 Alternative splicing of the CUGBP2 gene. (A) Schematic representation of the CUGBP2 protein and the CUGBP2 R3δ isoform. The
upper panel shows CUGBP2 and its domains. RRMs represent the RNA-binding domains. The NLS (line), NES (broken line), and splicing activation
domain (gray line) were determined in a previous report [27]. The lower panel shows the alternatively spliced form of CUGBP2, the R3δ isoform.
(B) Schematic representation of exon 14 and its adjacent region in the CUGBP2 gene. Exons are indicated as black boxes with the alternatively
spliced exons indicated as gray boxes. Introns are indicated by a central narrow line. Arrows show primer sites. (C) Expression analysis of CUGBP2
in adult mouse tissues. Semi-quantitative RT-PCR was performed using primers to detect the alternatively spliced exon of CUGBP2. The right side
indicates the positions of exon 14 skipping or inclusion products. b-Actin was used as a control. (D) Expression analysis of CUGBP2 in P19 neural
differentiation. The right side indicates the positions of exon 14 skipping or inclusion products. b-Actin was used as a control. Relative amounts
of exon 14 skipping and inclusion products were estimated by densitometry. Changes of total expression levels were normalized using brain
samples (C) or Day 0 samples (D). The error bars indicate the standard error. The values under the gel images indicate the percentage of the
exon 14 skipping in total CUGBP2 transcripts. (E) Western blot analysis of CUGBP2. Whole cell extracts of P19 cells (2 μg) were used to detect the
changes in the amount of full-length CUGBP2 in the upper panel. The middle panel shows the R3δ isoform detected using 7 μg of each extract.
GAPDH was used as a control and is shown in the lower panel.
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expression vector resulted in a decrease in the NM exon
product concomitant with an increase in the SM exon
product (Figure 3B & Additional file 1: Figure S1). Use of
the Etr-1 expression vector as a control showed that Etr-
1 promoted the use of the NM exon. These results are
consistent with previous reports [11].
To assess the function of the alternatively spliced iso-
form of CUGBP2 R3δ, transient transfection experiments
were performed using the ACTN1 minigene with the R3δ
instead of the CUGBP2 expression vector. R3δ induced
the production of the mutually exclusive SM exon similar
to CUGBP2 (Figure 3B & S1), suggesting that the func-
tion of R3δ in ACTN1 splicing is similar to that of
CUGBP2 and that part of RRM3, which is encoded in
R3δ, may be dispensable for the regulation of the splicing
of ACTN1. As shown above, our results identified the
brain as the location of SM exon inclusion and the kid-
ney and liver as characteristic of NM exon inclusion. In
parallel to SM exon inclusion, the expression level of
CUGBP2 was high in the brain and low in the kidney and
liver, suggesting that the upregulation of CUGBP2 in the
brain contributes to the induction of SM exon inclusion.
Different effects of CUGBP2 isoforms on the insulin
receptor
It was reported that CUGBP2 induces the skipping of
exon 11 in IR [17]. The induction of exon 11 skipping by
CUGBP2 was assessed using the IR minigene in transient
transfection experiments (Figure 3D). Transfection of
COS7 or HeLa cells with the IR minigene alone resulted
in the production of similar amounts of exon 11 inclu-
sion and skipping products (Figure 3E). Exon 11 inclu-
sion and skipping products were not detected in COS7
or HeLa cells without the minigene, confirming that they
were transcribed from the transfected minigene. Co-
transfection of the CUGBP2 expression vector and the IR
minigene caused an increase in the exon 11 skipping pro-
duct and a decrease in the exon 11 inclusion product
(Figure 3E & S1). Co-transfection of Etr-1 as a control
did not cause significant changes compared with the
transfection of the minigene alone (Figure 3E &3F).
These results confirmed that CUGBP2 induces the skip-
ping of exon 11, as previously reported. This effect was
clearer in HeLa cells than in COS7 cells (Figure 3E, data
not shown).
Figure 2 Expression analysis of the alternative splicing of the ACTN1 and IR genes. (A) Schematic representation of the mutually exclusive
splicing of the ACTN1 and IR genes. The genomic structure and alternatively spliced mRNAs of ACTN1 are shown in the left panel and those of
IR in the right panel. Exons are indicated as black boxes with alternatively spliced exons depicted as gray boxes. Introns are indicated with a
central narrow line. The arrow indicates the primer sites. (B) Expression analysis of ACTN1 and IR in P19 neural differentiation. Semi-quantitative
RT-PCR was performed using primers to detect the alternatively spliced exons as shown in Figure 2A. The right side shows the positions of the
SM exon and NM exon products or exon 11 skipping and inclusion products. (C) Expression analysis of ACTN1 and IR in adult mouse tissues.
Semi-quantitative RT-PCR was performed using primers to detect the alternatively spliced exons. The right side shows the positions of the
alternatively spliced products. b-Actin is shown as a control in Figure 1. The relative amounts of each PCR product were estimated by
densitometry. Total expression levels were normalized using Day 0 samples (B) or brain samples (C). The error bars indicate the standard error.
The values under the gel images indicate the percentage of the SM type or IRA in total ACTN1 transcripts or IR transcripts.
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To examine potential changes in the function of the
alternatively spliced isoform, R3δ, the IR minigene was
co-transfected with the R3δ expression vector, which
caused a decrease in exon 11 skipping and an increase in
exon 11 inclusion in comparison to co-transfection with
CUGBP2 or the mock control (Figure 3E & 3F). In a pre-
vious report, artificially truncated CUGBP2 proteins with
deleted N-terminal regions or deleted C-terminal regions
were unable to engage in efficient exon 11 skipping [17].
In the present study, R3δ promoted the exon 11 inclu-
sion, which is in contrast to the activity to full-length
CUGBP2, which promotes exon 11 exclusion of the IR
gene. These results also indicate that part of RRM3,
which is encoded by the alternative exon (exon 14) of
CUGBP2, is not only essential for the skipping of IR exon
11, but that disruption of this part of RRM3 may result in
a change in the splicing regulated by CUGBP2. Among
CELF family proteins, an isoform resembling R3δ can be
predicted in CELF4 (Table 1). However, a generalized
rule for RRM3s cannot be established because exon
11 skipping can be activated by a subgroup of proteins
that includes CUGBP1 and 2, but not by another sub-
group that includes Etr-1 (CELF3) or CELF4 (Figure 3E)
[17,29]. Our results suggest that the disruption of part of
RRM3 in CUGBP2 generates a new activity in the regula-
tion of the splicing of the IR gene. Because the R3δ iso-
form has a similar activity to CUGBP2 in the regulation
of splicing of ACTN1, it cannot be considered simply as a
dominant negative isoform of CUGBP2. The product of
exon 11 skipping was detected in the brain and the pro-
duct of exon 11 inclusion was detected in the kidney and
liver, suggesting that high CUGBP2 expression in the
brain contributes to exon 11 skipping. A high ratio of
R3δ to CUGBP2 in the kidney and liver may repress exon
11 skipping due to the specific function of the R3δ
isoform.
Figure 3 Transient transfection of the ACTN1 minigene and the IR minigene. (A) Schematic representation of the ACTN1 minigene. Exons
are indicated as black boxes with alternatively spliced exons indicated as gray boxes. Introns are indicated with a central narrow line. The arrows
show the primer sites. (B) Results of the transient transfection experiment. COS7 cells were transiently transfected with the ACTN1 minigene
with/without the CUGBP, CUGBP2 R3δ isoform, or Etr-1 expression vectors. Alternatively spliced products were analyzed by RT-PCR. (C)
Densitometric analysis of the transfection products. Quantification of the alternatively spliced products was performed by densitometry. The
percentage of SM exon inclusion with respect to total product is shown in graphical representation. The error bars indicate the standard error.
(D) Schematic representation of the IR minigene. Exons are indicated as black boxes and alternatively spliced exons are indicated as gray boxes.
Introns are shown with a central narrow line. The arrows show the primer sites. (E) Results of the transient transfection experiment. HeLa cells
were transiently transfected with the IR minigene with/without the CUGBP, R3δ isoform, or Etr-1 expression vectors. Alternatively spliced
products were analyzed by RT-PCR. (F) Densitometric analysis of the transfection products. Quantification of the alternatively spliced products
was performed by densitometry. The percentage of exon 11 inclusion with respect to total product is shown in graphical representation. The
error bars indicate the standard error.
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Structural analyses of the third RRM of the CUGBP2 R3δ
isoform
A total of 457 human RefSeq proteins with RRM
domain(s) were found in the BLAST. An RRM domain
is usually 70 ~ 80 a.a. in length, and slightly smaller
RRM domains (~ 60 a.a), which appear to lack rnp-2 in
the N-terminus or the dimerization module in the C-
terminal region, are frequently observed in conserved
domain searches of BLAST. RRM3 of CUGBP2 consists
of 75 a.a., and 44 a.a. of this region are disrupted in the
R3δ isoform. Disruption of almost half of RRM did not
prevent recognition of the remaining sequence in the
conserved domain search. A total of 53 human RefSeq
proteins (27 human genes) with severely disrupted RRM
domains are listed in Table 1. Some of the domains
shown in Table 1 such as eIF3B, eIF4B, La (SSB),
U2AF35 (U2AF1) and U2AF65 (U2AF65), have been
reported to form unusual RRM structures, although the
amino acid sequences were not sufficient to predict spe-
cific RRM structures [26,30-32].
There-dimensional structures of the RRM3 isoforms
were examined by MD simulation and NMR spectro-
scopy. The structural analysis of the RRM3 of CUGBP1
has been reported previously [22]. Several unaligned
residues were found between the RRM3s of CUGBP1,
and 2. The results of homology modeling showed that
the third domain of CUGBP2 formed an RRM structure
(Figure 4A). No significant difference could be observed
between the MD simulations of RRM3 of CUGBP1 and
RRM3 of CUGBP2. (data not shown). Further, CUGBP2
RRM3 maintained an RRM structure for 5 ns in the
MD simulation (Figure 4B). The 1H-15N HSQC spec-
trum of the RRM3 of CUGBP2 in the absence of RNA
showed that, unlike RRM3 of CUGBP1, the resonances
of the N-terminal residues in the linker domain were
concentrated in the center of the spectrum, suggesting a
random coil structure. This result was probably due to
the inclusion of a long N-terminal sequence in the pre-
sent constructs, which forms a flexible linker region
connecting RRM2 with RRM3 (Figure 5A).
Protein threading and comparative modeling of the
R3δ isoform were performed in the PDBj. The RRM3 of
human CUGBP1 was chosen as the ideal template in
the search and it was predicted that the R3δ isoform
with part of the linker sequence would not form an
RRM structure, especially as the first a-helix (a1) was
Figure 4 Structure transitions of the CUGBP2 and R3δ isoforms. (A) Initial structure of the CUGBP2 RRM3. The structure was predicted using
CUGBP1 RRM3 (2rq4a) because the amino acid sequences of RRM3 of CUGBP1 and 2 are almost identical. (B) MD simulation of the CUGBP2
RRM3. MD simulation was performed for 5 ns. (C) Initial structure of the R3δ isoform RRM3. The RRM3 and the linker residues of the R3δ isoform
were analyzed by comparative modeling by SFAS in PBDj. (D) MD simulation of the R3δ isoform. The result of comparative modeling was used
for MD simulation for 5 ns to analyze the folding and stability of the predicted structure.
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missing (Figure 4C). We used MD simulations to inves-
tigate whether the addition of linker residues to the
RRM domain could restore its structure. However, even
in these conditions, the first a-helix cannot be formed
even after 5 ns (Figure 4D). Moreover, resonances corre-
sponding to the R3δ isoform were detected in the cen-
tral region of the NMR spectrum, suggesting the
presence of greater alterations in the structure of R3δ
than those shown by MD simulation (Figure 5C) and
indicating that the RRM structure cannot be restored in
the R3δ isoform. In addition, the interaction between
CUGBP2 or the R3δ isoform and RNA molecules was
examined. The addition of RNA caused the disappearance
of many resonances and the appearance of new resonances
in CUGBP2 (Figure 5B). The affected residues, which are
highlighted with an open box in Figure 5B, were consistent
with the corresponding region of CUGBP1 [22] and indi-
cate that CUGBP2 binds to (UG)3 in a similar manner as
CUGBP1. No spectral changes were detected in the R3δ
isoform with the addition of RNA (Figure 5D), indicating
that the R3δ isoform does not bind to (UG)3.
Although the RNA-binding of RRM1-2 of CUGBPs is
still unclear, RRM3 is known to be responsible for RNA-
binding to UG-repeats [22]. MD simulation suggested
that the R3δ isoform could not form an RRM domain
and the NMR spectrum showed that it did not bind to
the UG-repeat. These results lead to the speculation that
the disruption of the first half of RRM3 by exon 14 skip-
ping causes a defect in RNA-binding. However, the R3δ
isoform may interact with ACTN1 pre-mRNA based on
the fact that this isoform still has two RRMs and two
different cis-elements were reported in the alternative
splicing of ACTN1 [11,12]. A CUGBP1 interacting cis-
element was determined in the intronic region of IR and
shown to affect the alternative splicing of IR [33].
Because this sequence is not a typical UG-repeat, perhaps
the RRM3 may not be responsible for the primary inter-
action with the IR pre-mRNA. Therefore, other, currently
unknown, proteins might interact with the RRM3
domain and it might be the interactions of these proteins
rather than RRM3 RNA-binding activity that is abrogated
by RRM3 alternative splicing.
Conclusion
The results of the present study show that while
CUGBP2 and its R3δ isoform similarly promoted the use
of the SM exon instead of the NM exon in the alternative
splicing of the ACTN1 minigene, they did not similarly
promote the use of exon 11 in the alternative splicing of
the IR minigene; CUGBP2 promoted skipping of exon 11,
Figure 5 1H-15N HSQC spectra of CUGBP2 and the R3δ isoform. The 1H-15N HSQC spectra of CUGBP2 and the R3δ isoform in the absence
(left) and presence of RNA (protein:RNA = 1:1, right). For clarity, only certain resonances are labeled with one-letter amino acid codes and
numbers [for further details, see Tsuda et al., 2009] [22]. The open boxes of panel B highlight the resonances that disappear with the addition of
(UG)3 RNA
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whereas R3δ did not. In addition, the results of MD
simulation and NMR suggested that the truncated RRM3
region in R3δ resulting from the alternative splicing of
CUGBP2 could neither form a new RRM domain nor
bind to a UG-repeat. Thus, it is possible that other, cur-
rently unknown, CUGBP2-interacting proteins and/or
other splicing factors involved in splicing regulation
might be important for RRM3 function. Our results also
showed that the skipping of exon 14 of CUGBP2 not
only disrupted CUGBP2 RNA-binding activity but also
altered its splicing regulator function. A high ratio of R3δ
to CUGBP2 in the kidney and liver may affect the spli-
cing of the IR gene and repress exon 11 skipping.
Methods
Plasmid construction
The entire open reading frame of CUGBP2 cDNA
(NM_001110228.1) and its alternatively spliced isoform,
CUGBP2 R3δ (NM_010160.2), were amplified by RT-PCR
using mouse brain total RNA and the following primers:
TGTACTCGAGATGCGCTGTCCCAAATCC and TCTG
TCTAGAGGATCAGTAAGGTTTGCTGTCG.The result-
ing cDNAs were subcloned into the pCS2+ MT vector
using Xho I and Xba I sites. RRM3 and RRM3 R3δ were
amplified by RT-PCR using the primers GCTC GGATC-
CATGGCGGCTCTGAATGG and TCTGCTCGAGGAT-
CAGTAAGGTTTGCTGTCG, and were subcloned into
the pGEX6P-1 vector using Bam HI and Xho I sites. The
coding sequence of Etr-1 was amplified by RT-PCR using
mouse brain total RNA and subcloned into the pCS2+ MT
vector. The preparation of the ACTN1 minigene was
described previously [34].
P19 cell culture and cell differentiation
Embryonic carcinoma P19 cells were cultured as described
elsewhere [35]. For neural differentiation, P19 cells were
allowed to aggregate in Petri dishes (Falcon) at a seeding
density of 1 × 105 cells/ml in the presence of 1 μM all-
trans-retinoic acid (RA, Sigma) in a-MEM (Minimum
Essential Medium, Sigma) supplemented with 10% FBS
(Fetal Bovine Serum, Sigma). After 4 days of aggregation,
cells were dissociated into single cells by 0.25% trypsin-
ethylenediaminetetraacetic acid (EDTA) (Sigma) solution
and replated in a tissue culture dish at a density of 3-6 ×
105 cells/ml. The cells were then allowed to adhere and
were cultured in the absence of RA for 10 days. Media were
replaced every 48 hours. COS7 and HeLa cells were grown
in DMEM (Dulbecco’s Modified Eagle’s Medium) supple-
mented with 10% FBS (Fetal Bovine Serum, Hyclone).
RNA purification and semi-quantitative RT-PCR
Purification of total RNA from P19 cells was performed
using the TRIzol reagent (Invitrogen) after the cells were
washed three times with ice-cold PBS. Total RNAs from
adult mouse tissues were commercially available
(Ambion, Toyobo). cDNA synthesis was performed by
SuperScript III (Invitrogen) with oligo-dT primers, using
1 μg of total RNA in 20 μl reaction mixture. PCR reac-
tions were carried out in 20 μl of reaction mixture con-
taining 1 μl of template cDNA, 0.1 U of Go Taq Flexi
DNA polymerase (Promega), 1 × GO Taq Flexi Buffer,
2.5 mM MgCl2, 0.2 mM dNTPs and 4 pmol of each pri-
mer. The PCR conditions consisted of an initial dena-
turation step at 95°C for 3 min, followed by a cycle of
denaturing at 95°C for 30 s, annealing at 60°C for 30 s,
and extension at 72°C for 30 s. The primer names,
sequences and number of cycles were as follows:
CUGBP2 exon 13, CACTGCCCACTTTGTACAGC, and
CUGBP2 exon 15, CTGATCCTAACCCCAGAAGC,
with 30 cycles; ACTN1 exon EF1a, CGCCTCTTTCAAC-
CACTTTG, and ACTN1 exon EF2, TCATGATTCGGG-
CAAACTCT with 27 cycles; and IR exon 10, CCTTC
GAGGATTACCTGCAC, and IR exon 12, TGTGCTC
CTCCTGACTTGTG, with 32 cycles. b-Actin was used
as an internal control as described previously [34]. PCR
products were analyzed in 6% polyacrylamide gels stained
with Ethidium Bromide (EtBr) and visualized in an UV-
trans illuminator (Vilber Lourmat). Each RT-PCR experi-
ment was performed more than three times. Quantitative
densitometry of the bands was performed using Image
Gauge software (Fuji Film).
Western blot analysis
Western blotting was performed according to a previously
described experimental protocol [36]. Cultured P19 cells
were washed with ice-cold PBS, collected in 1× buffer D,
and sonicated 3 times for 30 s on ice. One microgram and
2 μg of whole cell lysates were analyzed by 8% SDS-polya-
crylamide gel electrophoresis to detect full-length GAPDH
and CUGBP2, respectively. Because the expression level of
the R3δ isoform was low, 7 μg of lysate was used in one
lane. The positions of the full-length (56 kDa) and R3δ
(51 kDa) isoform were determined with molecular weight
markers (Bio-rad). Anti-CUGBP2 (GENWAY, 1:1000) and
anti-GAPDH (IMGENEX, 1:1000) were used as primary
antibodies. Anti-rabbit IgG-HRP (GE, 1:2000) conjugated
antibody was used as the secondary antibody to detect
CUGBP2 and R3δ proteins. Anti-goat IgG-HRP conju-
gated antibody (Invitrogen, 1:3000) was used as secondary
antibody to detect GAPDH. The experiments shown in
Additional file 1: Figure S1 were performed with 1 μg of
whole cell extracts and anti-myc (CST, 1:1,000) as a pri-
mary antibody and anti-rabbit IgG HRP conjugated anti-
body as a secondary antibody. The membranes were
treated using the ECL kit (GE), and the images were ana-
lyzed using the LAS-3000 analyzer (Fuji Film).
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Transient transfection experiments
Transient transfection experiments were carried out as
described previously [36]. Transfection was performed
using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. Total RNAs were isolated
from transfected cells using the TRIzol reagent (Invitro-
gen). cDNA synthesis was performed in Superscript III
(Invitrogen) with the T7 primer. PCR was performed as
described above using the IR exon 10 primer CCTGAAG-
GAGCTGGAGGAG and the IR exon 12 primer ACCGT
CACATTCCCAACATC with 25 cycles, and the primers
of ACTN1 exon EF1a and ACTN1 exon EF2 with 25
cycles. The PCR products were analyzed in 6% native poly-
acrylamide gels stained with EtBr. The images were then
visualized in an UV-transilluminator (Vilbar lourman).
Each transfection experiment was performed more than
three times. Quantitative densitometry of the bands was
performed using Image Gauge software (Fuji Film).
Protein expression
Fragments of CUGBP2 and the R3δ isoform were
expressed in Escherichia coli strain BL21(DE3) using the
pGEX-6P-1 expression plasmid. The two constructs for
GST-CUGBP2 and the GST-R3δ isoform were grown in
M9 minimal medium containing 1 g/L [15N] ammonium
chloride (Cambridge Isotope Laboratories) as the sole
source of nitrogen until an OD600 of 0.6 was reached,
followed by induction with 0.1 mM IPTG. The cultured
GST-CUGBP2 and GST-R3δ cells were allowed to grow
for an additional 8 hours at 30°C and 6 hours at 25°C,
respectively. The cells were harvested by centrifugation at
4,000 rpm for 20 min. The harvested cell pellets of
CUGBP2 and the R3δ isoform were resuspended in buffer
1 [50 mM Tris-HCl (pH 8.0) and 1 mM DTT] and buffer
2 [20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 50 mM gly-
cine ethyl ester, 25 mM arginine, 25 mM glutamic acid
and 10 mM DTT], respectively. The cell solutions were
lysed by sonication and the lysate was clarified by centrifu-
gation at 15,000 rpm for 20 min followed by filtration with
a 0.45 μm membrane.
Purification of CUGBP2 and the R3δ isoform
Protein lysates were loaded onto a Q-Sepharose column
and eluted with a stepwise concentration gradient of
100-300 mM NaCl in 20 mM Tris (pH 8.0) buffer. Frac-
tions containing GST-tagged CUGBP2 were identified
using SDS-PAGE. A HiLoad 16/60 Superdex 75 column
(GE Healthcare) connected to an AKTA prime plus (GE
Healthcare) was equilibrated with 20 mM Tris-HCl buf-
fer (pH 8.0) containing 150 mM NaCl and 1 mM DTT
with a flow rate of 1.0 mL/min. The sample was concen-
trated and applied to the column.
Fractions containing GST-tagged CUGBP2 were identi-
fied using SDS-PAGE and pooled. CUGBP2 was cleaved
from the GST-tagged protein by 40 units of PreScission
protease and extensively dialyzed against PreScission pro-
tease cleavage buffer [50 mM Tris-HCl (pH 7.0), 150 mM
NaCl, 1 mM EDTA and 1 mM DTT] at 4°C for 48 hours.
The cleaved proteins were again applied to a gel filtration
column. Finally, CUGBP2 was applied to a GST column,
and the flow-through fractions were collected. The pure
protein solution was dialyzed extensively against a 20
mM NH4HCO3 solution and then lyophilized.
The GST-tagged R3δ isoform was isolated from soni-
cated cell extracts with a glutathione Sepharose 4 Fast
Flow (GE Healthcare) column according to a standard
protocol. The R3δ isoform was cleaved from the fusion
protein by PreScission protease and the GST-tags were
removed with a GST column under the same conditions
as those used for CUGBP2. Finally, the R3δ isoform was
purified by a reverse phase HPLC COSMOSIL C18 col-
umn (10 mm I.D. × 250 mm, Nacalai Tesque Inc.) pro-
tected by a guard column. Eluent A was 100% water with
0.1% (v/v) trifluoroacetic acid (TFA); eluent B was 99.8%
(v/v) acetonitrile with 0.1% (v/v) TFA. The gradient was as
follows: 0 min, 5% B; 5 min, 5% B; 70 min, 70% B. The
flow rate was 2 mL/min. The UV wavelength was 280 nm.
Protein fractions from 50-51 min were collected, dialyzed
and then lyophilized.
Nuclear magnetic resonance (NMR) spectroscopy
For NMR measurements, the samples were concentrated
to 0.1 mM in 20 mM Bis-Tris (pH 7.0) containing
100 mM NaCl, 1 mM 1,4-DL-dithiothreitol-d10 (d-DTT)
and 0.02% NaN3 (in 90% H2O/10% D2O), using an Ami-
con Ultra-4 filter (3000 MWCO, Millipore). The NMR
experiments were performed for the RNA-free forms and
for the RNA-bound forms on an 800 MHz spectrometer
(Bruker AVANCE III 800) equipped with a TCI-cryogenic
probe at 15°C. The NMR data were processed using
NMRPipe [37]. Analyses of the processed data were per-
formed with the program NMRViewJ [38]. The 15N che-
mical shift was calculated by using the ratio, gN/gH =
0.101329118.
Comparative modeling and molecular dynamics
simulation
Comparative modeling was performed in the PBDj site
http://sysimm.ifrec.osaka-u.ac.jp/sfas/. MD simulations
were carried out to confirm the structural stability of
the RRM3 conformation in CUGBP2 and CUGBP2 R3δ.
Detailed information on these proteins and the MD
conditions used is provided in Table 2. The pdb files of
prediction and simulation are available as Additional
file: Additional file 2A is the pdb for the RRM3 of
CUGBP2 at 0 ns, Additional file 3: 2B shows the pdb
for CUGBP2 at 5 ns, Additional file 4: 2C is the pdb for
R3δ at 0 ns, and Additional file 5: 2D corresponds to
Suzuki et al. BMC Biochemistry 2012, 13:6
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the pdb for R3δ at 5ns. MD simulations were carried
out by using the AMBER10 program package with force
field 03 [39]. Simulation time was 5 ns (Δt = 1fs) at
room temperature (300K) with periodic boundary
conditions.
Additional material
Additional file 1: Figure S1. Transient transfection of the effectors with
the ACTN1 minigene or the IR minigene. Transient transfection
experiments with the ACTN1 minigene (upper panel) or the IR minigene
(lower panel) were performed as shown in Figure 3. Whole cell extracts
were analyzed by western blot analysis using an anti-Myc or anti-GAPDH
antibody. Endogenous expression of GAPDH and over-expressing
effectors containing CUGBP2, R3δ, and Etr-1 were observed.
Additional file 2: Additional file 1A. The pdb file of the predicted
CUGBP2 RRM3 at 0 ns.
Additional file 3: Additional file 1B. The pdb file of the simulated
CUGBP2 RRM3 at 5 ns.
Additional file 4: Additional file 1C. The pdb file of the predicted
structure, which contains the partial RRM3 and linker region in CUGBP2
R3δ, at 0 ns.
Additional file 5: Additional file 1D. The pdb file of the simulated
structure, which contains the partial RRM3 and linker region in CUGBP2
R3δ, at 5 ns.
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